MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413970 | Name: Dutogliptin Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dutogliptin Free Base is an orally available, potent, and selective di-peptidyl peptidase 4/DPP4 inhibitor that improves glycemic control in type 2 diabetic patients.

Chemical Structure

Dutogliptin Free Base
Dutogliptin Free Base
CAS#852329-66-9 (free base)

Theoretical Analysis

MedKoo Cat#: 413970

Name: Dutogliptin Free Base

CAS#: 852329-66-9 (free base)

Chemical Formula: C10H20BN3O3

Exact Mass: 241.1598

Molecular Weight: 241.09

Elemental Analysis: C, 49.82; H, 8.36; B, 4.48; N, 17.43; O, 19.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
852329-66-9 (free base) 890402-81-0 (tartrate)
Synonym
Dutogliptin Free Base; PHX 1149; PHX-1149; PHX1149
IUPAC/Chemical Name
Boronic acid, ((2R)-1-(((3R)-3-pyrrolidinylamino)acetyl)-2-pyrrolidinyl)-
InChi Key
DVJAMEIQRSHVKC-BDAKNGLRSA-N
InChi Code
InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1
SMILES Code
O=C(N1[C@H](B(O)O)CCC1)CN[C@H]2CNCC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 241.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Johnson KM. Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs. 2010 Apr;11(4):455-63. PMID: 20336594. 2: Buchtele N, Schwameis M, Schoergenhofer C, Derhaschnig U, Firbas C, Karch R, Nix D, Schenk R, Jilma B. Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose- escalating trial. Br J Clin Pharmacol. 2020 May;86(5):979-990. doi: 10.1111/bcp.14208. Epub 2020 Feb 11. PMID: 31912513; PMCID: PMC7163368. 3: Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. doi: 10.1111/j.1463-1326.2010.01195.x. PMID: 20380656. 4: Marier JF, Mouksassi MS, Gosselin NH, Li J. Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. Clin Pharmacol Drug Dev. 2014 Jul;3(4):297-304. doi: 10.1002/cpdd.87. Epub 2014 Feb 10. PMID: 27128836. 5: Li J, Klemm K, O'Farrell AM, Guler HP, Cherrington JM, Schwartz S, Boyea T. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients. Curr Med Res Opin. 2010 Aug;26(8):2003-10. doi: 10.1185/03007995.2010.491266. PMID: 20583949. 6: Wang B, Sun Y, Sang Y, Liu X, Liang J. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis. Medicine (Baltimore). 2018 Nov;97(46):e12633. doi: 10.1097/MD.0000000000012633. PMID: 30431561; PMCID: PMC6257459. 7: von Lewinski D, Selvanayagam JB, Schatz RA, Jilma B, Kubica J, Povsic TJ, Nix D, Henauer S, Wallner M; REC-DUT-002 study group. "Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial. Trials. 2020 Aug 26;21(1):744. doi: 10.1186/s13063-020-04652-0. PMID: 32843081; PMCID: PMC7448478. 8: Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin Investig Drugs. 2011 Jun;20(6):723-32. doi: 10.1517/13543784.2011.576667. Epub 2011 Apr 18. PMID: 21500969. 9: Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen. IDrugs. 2010 Mar;13(3):145-8. PMID: 20191426. 10: Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012 Jan;29(1):14-25. doi: 10.1007/s12325-011-0088-z. Epub 2011 Dec 22. PMID: 22215383.